Objectives: Osteoarthritis (OA) is the most common joint disease, characterized by cartilage degeneration and disordered repair. Most cases are idiopathic, occurring insidiously due to aging, while a minority of cases is due to underlying systemic diseases. Many complain of debilitating pain affecting quality of life. Although studies exist comparing various clinical parameters with severity of osteoarthritis; few studies have examined the correlation between clinical and histopathologic assessment. Our objective is to correlate clinical severity and histopathologic grading of osteoarthritis. Methods: Ten patients were evaluated subjectively by pain scale (0 none, 10 unbearable), objectively by Outerbridge arthroscopic scoring (OBS) and Kellgren Lawrence (KL) radiologic classification. Clinically severe osteoarthritic patients underwent total knee replacement. The bone was fixed in formalin, decalcified, paraffin embedded, and cut at 4 um. Sections were stained with H&E, toluidine blue, and safranin-o, and graded using the OARSI cartilage grading system. Results: All patients evaluated had good clinical (high pain scores, high OBS and KL scores) and histopathologic correlation. Five of 10 had pain scores of 10, OBS and KL scores 3 to 4 (severe OA), and OARSI grades 5 to 6 (severe OA). Three had pain scores 6 to 10, OBS grade 4, KL grades 2 to 4 (moderate to severe OA), and OARSI grades 5 to 6 (severe OA). Two had no pain scores recorded, but their OBS scores were 4, KL grades were 3 and 4, and OARSI grades were both 5.
Conclusion:
The severity of osteoarthritis is determined clinically by various parameters including pain, and radiologic and arthroscopic findings. These factors determine quality of life and surgical indications. When compared to histopathology, the clinical severity of osteoarthritis shows good correlation with pathologic grading. This study proves that the use of clinical parameters is a reliable indicator for determining who may benefit from surgical intervention. 
Objectives:
Colonoscopy has been shown to reduce colon cancer incidence and risk of death. The risk of progression to carcinoma depends upon the size and number of adenomas with a higher risk in advanced adenomas. Our objective was to evaluate the prevalence of adenomas and advanced adenomas, discovered during free screening colonoscopy, in 52 asymptomatic patients of non-Caucasian ethnicity, predominantly African Americans (AAs). Methods and Materials: This is a retrospective study of 52 patients who underwent free screening colonoscopy in 2016 at an urban hospital serving ethnic minorities. There were 47 AA, three Hispanics, one Asian, and one Caucasian patient enrolled in the study. Twenty-eight were men, and 24 were women. The tissue samples were examined under microscope with standard hematoxylin and eosin stain. The diagnoses of adenoma and advanced adenoma were based on established criteria. Results: Polyps were identified in 51/52 (98%) patients including all women and 27/28 (96%) men. Adenomas were detected in 78.8% cases and advanced adenomas in 35% cases. The adenoma detection rate (ADR) was 92% in men and 81% in women. The advanced adenoma detection rate (AADR) was 27% in men and 42% in women. Conclusion: Our study shows a high prevalence of adenomas and advanced adenomas in AA population when compared to the general population (9.7%-60.5% for men, 3.9%-45.9% for women). Advanced adenoma is defined by the presence of one of the following: highgrade dysplasia, villous component >25%, and/or size >1 cm. The presence of advanced adenoma requires complete excision with clear margins and more frequent surveillance colonoscopy due to a high risk of malignant transformation. Our findings suggest that more frequent colonoscopy may be warranted in AAs. Further studies Objectives: Normal eosinophils can be found as high as 35 per high power field in lamina propria of the cecum. However, number of the eosinophils appears to be reduced along the mucosa to distal colon. This might represent an antigen process of food waste involved by eosinophils. A previous study suggests that more than 10 eosinophils in the rectal mucosa may represent an allergic etiology in pediatric population but the actual mean value of eosinophils in rectal mucosa in adults remains unclear. Methods: This study was to investigate the baseline level of eosinophils in rectal mucosa from men underwent trans-rectal prostate biopsies (assuming absence of gastrointestinal symptoms in them). From 30 men with incidental "snap-out" colonic mucosa present in our archival prostatic biopsies, the high eosinophil counts in the lamina propria of rectal mucosa per high power field were recorded. Results: Mean value ± standard error was 0.9 ± 0.26 (range 0-4 eosinophils), which was significantly lower than those of six adult positive controls (22.33 ± 3.11, ranging from 12 to 30 eosinophils per high power field) with either inflammatory bowel disease or unknown etiology of active colitis. Conclusion: The evaluation of incidental rectal mucosa from prostate biopsies has provided us with normal range of rectal eosinophils not more than four eosinophils per high power field, compatible with a notion that rectal mucosa may be involved in less antigen processing than that of initial portion of colon (cecum). Progression to muscle-invasive disease significantly reduces five-year survival rates to 63% (SEER), and an important component of disease progression involves epithelial to mesenchymal transition. We therefore investigated E-cadherin expression and localization in the progression to pT1 and pT2 invasive disease. Methods: This retrospective study design involved 60 patients who had an initial diagnosis of pTa (NILG n = 7; NIHG n = 10), pTis (n = 30), and pT1 disease (n = 13), with a mean follow-up of 96 months to assess for progression. Initial biopsies diagnosed as pTa/pTis/pT1 disease were immunostained for E-cadherin, and membrane staining was evaluated for focal or extensive loss. Results: Of the 47 patients with non-invasive disease, we identified 20 progressors that included 0 NILG (0%), four NIHG (9%), and 16 patients with CIS (34%). Mean follow-up in these three cohorts was 93, 87, and 119 months, respectively. Loss of E-cadherin was identified in a small subset of these patients and included one of four NIHG progressors (25%), five of 16 CIS progressors (31%), and two of five pT1 progressors (40%). When comparing to the nonprogressor cohort, E-cadherin loss unexpectedly appeared equivalent to or more prevalent than the progressor cohort [one of six NIHG (17%), eight of 14 CIS (57%), and six of eight pT1 (75%) 
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